检索结果-南通市图书馆

shift current photovoltaic efficiency of 2D materials

npj Computational Materials 2023年第1期9卷 1991-1999页

作者： Mikkel Ohm Sauer Alireza Taghizadeh Urko Petralanda Martin Ovesen Kristian Sommer Thygesen Thomas Olsen Horia Cornean Thomas garm Pedersen Department of Materials and Production Aalborg University9220 AalborgØstDenmark Department of Mathematical Sciences Aalborg University9220 AalborgØstDenmark Center for Nanostructured Graphene(CNG) 9220 AalborgØstDenmark Computational Atomic-scale Materials Design(CAMD) Department of PhysicsTechnical University of Denmark2800 Kgs.LyngbyDenmark Department of Physics University of the Basque Country(UPV/EHU)Apartado 644Bilbao 48080Spain Center for Nanostructured Graphene(CNG) 2800 Kgs.LyngbyDenmark

shift current photovoltaic devices are potential candidates for future cheap,sustainable,and efficient electricity *** the present work,we calculate the solar-generated shift current and efficiencies in 326 different 2D materials obtained from the computational database *** apply,as metrics,the efficiencies of monolayer and multilayer *** monolayer efficiencies are generally found to be low,while the multilayer efficiencies of infinite stacks show great ***,the out-of-plane shift current response is considered,and material candidates for efficient out-of-plane shift current devices are *** the screened materials,MXY Janus and MX_(2) transition metal dichalchogenides(TMDs)constitute a prominent subset,with chromium based MXY Janus TMDs holding particular ***,in order to explain the band gap dependence of the PV efficiency,a simple gapped graphene model with a variable band gap is established and related to the calculated efficiencies.

关键词： shift database multilayer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Prognostic Value of Cell-Free DNA in Advanced Non-Small-Cell Lung Cancer

引用

Journal of Cancer Therapy 2013年第8期4卷 1-7页

作者： Anneli Dowler Nygaard Karen-Lise garm Spindler Niels Pallisgaard Rikke Fredslund Andersen Anders Jakobsen Department of Biochemistry Vejle Hospital Vejle Denmark Department of Oncology Vejle Hospital Vejle Denmark

Background: Cell-free DNA (cfDNA) holds promise as a tumor marker of clinical importance. We aimed to investigate the prognostic value of baseline cfDNA in non small-cell lung cancer (NSCLC). Material and Methods: During a three-year period, patients with newly diagnosed, previously untreated advanced NSCLC were included in a consecutive, prospective marker-trial. Plasma was isolated from a pre-treatment peripheral blood sample and the level of total cfDNA was measured by an in-house assay qPCR-method. The treatment comprised carboplatin (AUC 5) intravenously day 1), and vinorelbine (30 mg/m2 intravenously day 1 and 60 mg/m2 perorally day 8) q3w for a maximum of six cycles. The primary end-point was overall survival (OS). Secondary end-points were progression free survival (PFS) and overall response rate (ORR). Results: 245 patients were included and received a minimum of 1 cycle of chemotherapy (median 4). The median OS was 8.9 months, the median PFS by intention to treat 5.4 months and the ORR was 25%. The patients were divided into four groups based on quartiles of cfDNA and subsequently dichotomized by the 75th percentile revealing a significantly worse prognosis for patients in the upper 75th percentile (median OS 4.9 months) compared to patients with lower levels (10.0 months) (HR 2.1, 95%CI 1.4 - 3.1, p 0.0001). A multivariate analysis confirmed the independent prognostic value of cfDNA. A subgroup analysis of patients with high cfDNA and poor performance status (PS = 2) identified a group of patients with even worse prognosis (median OS 2.0 versus 9.1 months, HR 3.6, 95%CI 1.4 - 9.2, p 0.0001). Similar and significant results were found when comparing level of cfDNA and PFS. Conclusions: High pre-treatment level of cfDNA seems to have a strong prognostic impact in patients with newly diagnosed advanced NSCLC. Combined with PS it identifies a patient group with minimal or no benefit of chemotherapy.

关键词： Cell-Free DNA Prognostic NSCLC Circulating DNA

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pemetrexed and Gemcitabine for Chemotherapy Refractory Colorectal Cancer—Results of a Phase II and Translational Research Study

引用

Journal of Cancer Therapy 2013年第6期4卷 44-50页

作者： Karen-Lise garm Spindler Niels Pallisgaard Rikke Fredslund Andersen John Ploen Anders Jakobsen Department of Biochemistry Vejle Hospital Vejle Denmark Department of Oncology Vejle Hospital Vejle Denmark

Introduction: We investigated the safety and efficacy of pemetrexed with gemcitabine in heavily pre-treated, chemotherapy refractory, KRAS mutated colorectal cancer (mCRC) and the prognostic value of quantitative levels of cell free DNA (cfDNA) in plasma. Methods: Inclusion criteria comprised;histopathologically verified, KRAS mutant, chemotherapy resistant mCRC, adequate organ function and performance status. Patients received pemetrexed (initially 500 mg/m2 q3w) + gemcitabine (1250 mg/m2 days 1 and 8) until progression or unacceptable toxicity. RECIST version 1.1, NCI-CTCAE version 4.0 and Kaplan-Meier statistics were used for endpoint evaluation. Cell free DNA was quantified from pre-treatment EDTA plasma-samples by an in-house qPCR. Results: Forty patients were included. The median number of cycles was 3 (range 0 - 12). Thirty-six percent obtained disease stabilisation, but?no objective response was observed. Median PFS and OS were 2.8 (range 2.1 - 4.0) and 5.4 (range 4.3 - 7.0) months, respectively. Adverse events caused immediate discontinuation of treatment or delay of the next cycle and consequently discontinuation in 5 patients. Translational research revealed a shorter PFS and OS with increasing levels of cfDNA. The median PFS in patients with cfDNA levels above the 75 percentile was 2 months compared to 4 months in the remaining patients, HR 3.23 (1.05 - 9.89), p = 0.0008. The median OS was 3 and 6 months, respectively, HR 2.9 (95%CI 0.98 - 8.34). Cox regression analysis confirmed that cfDNA remained a significantly independent prognostic factor for both PFS and OS. Conclusion: Pemetrexed and gemcitabine did not prove sufficient benefit and unacceptable toxicity was observed. The potential value of cfDNA should be investigated further.

关键词： Metastatic Colorectal Cancer KRAS cfDNA Plasma Pemetrexed Gemcitabine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：